• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Lercanidipine Hydrochloride

Lercanidipine Hydrochloride

Product ID L1869
Cas No. 132866-11-6
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $68.30 In stock
50 mg $131.30 In stock
250 mg $183.80 In stock
1 g $262.50 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Lercanidipine is a dihydropyridine calcium channel blocker. It significantly countered wall thickening and luminal narrowing on small sized arteries. This compound and other similar dihydropyridine-type Ca2+ antagonists exert protective effect on retinal that include reduced thickness of retina and of inner plexiform, outer nuclear and layer of inner and outer segments plus outer limiting layer, and loss of ganglionic neurons. Lercanidipine consistently decreased MMP-9 activity and reduced oxidative stress in hypertensive patients. Lercanidipine treatment of spontaneously hypertensive rats (SHR) during 6 weeks was able to revert the deleterious effects of hypertension on cortical bone density and on the number of TRAP+ cells in the tibia of SHR.

Product Info

Cas No.

132866-11-6

Purity

≥98%

Formula

C36H41N3O6・HCl

Formula Wt.

648.20

Chemical Name

5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride

IUPAC Name

1-[(3,3-Diphenylpropyl)(methyl)amino]-2-methyl-2-propanyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride (1:1)

Synonym

Cardiovasc, Corifeo

Solubility

Soluble in DMSO (100 mM), ethanol (10 mM), water (partly), chloroform, and methanol.

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

L1869 MSDS PDF

Info Sheet

L1869 Info Sheet PDF

References

Sabbatini M1, Leonardi A, Testa R, et al. Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2002 Jan;39(1):39-48. PMID: 11743226.

Sabbatini M1, Tomassoni D, Di Tullio MA, Amenta F. Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clin Exp Hypertens. 2002 Oct-Nov;24(7-8):727-40. PMID: 12450247.

Martinez ML1, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan;47(1):117-22. PMID: 16424795.

Bastos MF1, Vasconcelos de Araújo I, et al. Effects of lercanidipine on bone density and bone repair in spontaneously hypertensive rats. Implant Dent. 2013 Feb;22(1):49-54. doi: 10.1097/ID.0b013e3182777650. PMID: 23287976.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P2000

    PF-03758309 Dihydrochloride

    PAK4 inhibitor.

    ≥99%, ≥99%ee
  • A2501

    AG-1517

    EGFR inhibitor.

    ≥98%
  • M568262

    Mogrol

    Triterpenoid

    ≥99%
  • T0081

    Taurine

    Endogenous sulfonic acid involved in Ca2+ signa...

    ≥99%
  • D3352

    Dinaciclib

    BRD binding agent, CDK1/2/5/9 inhibitor.

    ≥99%
  • T5871

    Torin 2

    Tricyclic benzonaphthyridinone; mTORC1/2 inhibi...

    ≥98%
  • L589921

    Loxapine Succinate

    D2 and D4 dopamine receptor inhibitor.

    ≥99%
  • L1786

    Levofloxacin Hydrochloride Monohydrate

    Fluoroquinolone, S-(-) isomer of ofloxacin; top...

    ≥90%
  • N7209

    NSC-207895

    Benzofuroxan derivative; MDMX inhibitor.

    ≥98%
  • G6817

    Green Tea Polyphenols

    Extract containing catechins and flavonoids fou...

    ≥98%
  • D0375

    Dasatinib Monohydrate

    Abl, PDGFR, EphR, Src, k-Kit, FYN, LCK, HCK inh...

    ≥98%
  • M4000

    MK-2206 Monohydrochloride

    Akt inhibitor.

    ≥99%
  • N5669

    Nordihydroguaiaretic Acid

    Phenol found in the creosote bush; 5-lipoxygena...

    ≥99%
  • C2961

    Chondroitin Sulfate, chicken

    Polyanionic sulfated glycosaminoglycan, endogen...

    ≥90%
  • H9717

    Hydroxyzine Dihydrochloride

    FIASMA, histamine H1 inverse agonist, 5-HT2A, D...

    ≥98%
  • F1607

    Febuxostat

    Xanthine oxidase inhibitor.

    ≥98%
  • I7870

    Itraconazole

    Triazole; 14-α demethylase inhibitor, Smo modu...

    ≥98%
  • T5769

    Toremifene Base

    SERM, androgen modulator.

    ≥98%
  • A7208

    Ascomycin

    FK506 analog; calcineurin inhibitor.

    ≥98%
  • S8253

    Sunitinib Malate

    Indoline; PDGFR, VEGFR, c-KIT, FLT3, mTORC1 inh...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only